30 closest matches · ranked by relevance
Ovarian Carcinoma · Breast Cancer
Primary: Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines — 75; 30.77; 0; 25.58 Percentage of participants
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate (ORR) — 109; 37 Count of Participants — p=0.002
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Primary: Objective Response Rate, Defined as the Percentage of Subjects With a Best Overall Response of Confirmed Complete Response (CR) or Partial Response (PR) — 69.3; 64.0…
Ovarian Cancer · Breast Cancer
Primary: Haematology: Basophils Absolute Count, Eosinophils Absolute Count, Leucocytes WBC, Lymphocytes Absolute Count, Monocytes Absolute Count, Neutrophils Absolute Count, and…
Ovarian Cancer · Fallopian Tube Cancer · Primary Peritoneal Carcinoma
Primary: Progression-free Survival — 8.85; 8.32 months
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants
BRCA1 Gene Mutation · BRCA2 Gene Mutation · Ovarian Serous Adenocarcinoma
Primary: Incidence of Dose-limiting Toxicities (DLTs) Defined as the Rate of Drug-related Grade 3-5 Adverse Events Assessed Using the National Cancer Institute Common Terminology…
Breast Cancer
Primary: Overall Response Rate (ORR) Per RECIST1.1 — 7 Participants
Ovarian · Breast · Prostate
Primary: Tumour Response Rate — 12.9; 31.1; 21.7; 50 Percentage of participants
Breast Cancer Metastatic · BRCA 1 Gene Mutation · BRCA 2 Gene Mutation
Primary: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) — 7.0…
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Germline BRCA1/2 Mutations and · Metastatic Adenocarcinoma of the Pancreas
Primary: Progression-free Survival (PFS) by Blinded Independent Central Review (BICR) Using Modified Response Evaluation Criteria in Solid Tumours. This Study Used Modified…
BRCA or HRR+ Mutated Ovarian Cancer Patients
Primary: Progression-Free Survival (PFS) — 18.0; 16.6 months
Pancreatic Cancer
Primary: Number of Participants Who Experienced a Dose Limiting Toxicity to Determine the Maximum Tolerated Dose (MTD) — 0; 2; 2 participants
Breast Cancer · Metastatic Breast Cancer · BRCA1 Gene Mutation
Primary: Objective Response Rate (ORR) of ABT-888 and Temozolomide (TMZ) in Metastatic Breast Cancer — 4; 3 Participants
HER2-ve Metastatic Breast Cancer · Germline BRCA1/2 Mutations · Somatic BRCA1/2 Mutations
Primary: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants — 8.18 months
Non-Germline BRCA Mutated Ovarian Cancer
Primary: Progression Free Survival (PFS) — 9.2 months
Breast Cancer
Primary: Two-year Disease Free Survival — 54.2; 64.1 percentage of participants
Advanced Ovarian Cancer · Primary Peritoneal Cancer · Advanced Breast Cancer
Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…
Metastatic Breast Cancer
Primary: Progression-Free Survival (PFS) — 12.6; 14.6 months — p=0.003
Ovarian Cancer
Primary: PFS — 29.8 Months
Breast Cancer
Primary: Disease-free Survival — 5.44; 5.45 DFS events/100*person-year
Ovarian Neoplasm
Primary: Confirmed Objective Tumour Response (According to Response Evaluation Criteria In Solid Tumors (RECIST) — 3; 11; 3; 11 Participants
Advanced Breast Cancer
Primary: Overall Response Rate (ORR) — 1 Participants
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Neoplasms
Primary: Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed…
Metastatic Breast Cancer · Breast Neoplasms
Primary: Time to Treatment Failure (TTF) for Talazoparib — 5.5 Months
Breast Cancer
Primary: Overall Response Rate (ORR) — 40.7; 5.0; 8.8 percentage
Ovarian Cancer · Breast Cancer
Primary: Maximum Plasma Concentration During the Dosing Interval at Steady State (CmaxSS) — 10395.085; 9676.278 ng/mL
Advanced Breast Cancer · HER2/Neu Negative · Triple-Negative Breast Cancer
Primary: Objective Response (OR) — 0; 0; 0; 3 Participants
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants